XyloCor Therapeutics is a biopharmaceutical company focused on developing gene therapy for advanced coronary artery disease.

XyloCor Therapeutics

XyloCor Therapeutics is a development-stage, biotechnology company dedicated to developing first-in-class gene therapies for patients with unmet medical need in cardiovascular disease.

Sofinnova Investments

Fountain Healthcare Partners

EQT life science

Longwood Fund

Lumira Ventures

XyloCor Therapeutics, Inc.

Today our CEO Al Gianchetti was interviewed by Ali Gorman of BiotechTV and they discussed the exciting progress XyloCor is making with the clinical development of XC001 for patients with refractory angina. In addition, they discussed XyloCor's recent agreement with SmartCella which enables XyloCor to use their Extroducer catheter (use the title from the press release) to deliver XC001 to the heart without the need for a surgical procedure. 
#Philly #biotech #cardiovascular #genetherapy
https://lnkd.in/g_ADHVMV

#NEWS: Today, we announced an agreement with Smartwise , a unit of SmartCella Holding AB (“SmartCella”). We have entered into a licensing agreement under which XyloCor has rights to the Extroducer® Infusion Catheter System ®, a first-in-class endovascular device designed to deliver advanced therapies directly into the heart [and hard-to-reach tissues]. XyloCor plans to deploy the Extroducer to support catheter-based endocardial delivery of its lead gene therapy candidate, XC001 (encoberminogene rezmadenovec), in future clinical studies and commercial use. 
Read more here: https://lnkd.in/edyPaxJy   
 #GeneTherapy #HeartDisease #Innovation #cardiovascular

Thank you to Laurie Glimcher, Ivana Magovcevic-Liebisch, PhD, JD, Maria Whitman, Al Gianchetti & Brian Alexander for the important #patientcentricity discussion #longwoodhealthcareleaders Longwood Fund

#NEWS: Today, we announced positive Phase 2 data for our refractory angina treatment candidate, a novel therapeutic approach that aims to fill a significant unmet medical need for people who have exhausted available treatment options and have a debilitating quality-of-life. Our #clinicaltrial results were also presented today at the  Society for Cardiovascular Angiography & Interventions 2024 Scientific Sessions and will be published in the medical journal Circulation: Cardiovascular Interventions. Read more here: https://lnkd.in/edyPaxJy  
#SCAI2024
 #GeneTherapy #HeartDisease #Innovation

Happy Holidays from the XyloCor family to yours.

XYLO

COM:XYLOCOR

XyloCor Therapeutics